Primary information |
---|
sequence ID | Seq_8613 |
Peptide sequence | TTAVVTNPKE |
CancerPDF_ID | CancerPDF_ID9900, CancerPDF_ID12502, |
PMID | 21533267,26992070 |
Protein Name | Transthyretin,Transthyretin |
UniprotKB Entry Name | TTHY_HUMAN,A6XGL1_HUMAN |
Fluid | Serum,Serum |
M/Z | 530.27,NA |
Charge | 2,NA |
Mass (in Da) | NA,1059.567675 |
fdr | NA,NA |
Profiling Technique | LC-MS,LC-MS |
Peptide Identification technique | LC/MS/MS,LC-MS/MS |
Quantification Technique | Multiple Reaction Monitoring,NA |
Labelled/Label Free | Label Free,Label Free |
FDR | 1.49,FDR 1 % |
CancerPDF_ID | CancerPDF_ID9900, CancerPDF_ID12502, |
p-Value | NA,NA |
Software | MASCOT,SEQUEST and Maxquant |
Length | 10,10 |
Cancer Type | Lung adenocarcinoma,Melanoma |
Database | Swissprot Database (57.4),SwissProt Database |
Modification | NA,NA |
Number of Patients | 62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples |
Regulation | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Present in 6 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples." |
Validation | MRM-based validation of 19 candidates,na |
Sensitivity | NA,NA |
Specificity | NA,NA |
Accuracy | NA,NA |
Peptide Atlas | PeptideAtlas |
IEDB | 181253
439049
|